<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998799</url>
  </required_header>
  <id_info>
    <org_study_id>ATCOVIDIndia</org_study_id>
    <nct_id>NCT04998799</nct_id>
  </id_info>
  <brief_title>Practice Variation on Antithrombotics in COVID-19</brief_title>
  <official_title>Current Practices on Antithrombotic Therapy in Hospitalised and Discharged Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NMC Specialty Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NMC Specialty Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evidence suggests coronavirus disease 2019 (COVID-19) is associated with an increased&#xD;
      incidence of thromboembolic manifestations. Various guidelines on managing antithrombotics in&#xD;
      COVID-19 either provided conflicting guidance or unclear recommendations for post-discharge&#xD;
      thromboprophylaxis.&#xD;
&#xD;
      The investigators aim to collect the current practices in India among physicians on&#xD;
      antithrombotic therapy for hospitalised patients with COVID-19 and after discharge from the&#xD;
      hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune dysregulation plays a crucial role in the development of severe coronavirus disease&#xD;
      2019 (COVID-19). The autopsy of lungs in deceased COVID-19 patients showed micro thrombosis&#xD;
      and inflammatory infiltrates similar to acute respiratory distress syndrome (ARDS). Reports&#xD;
      of increased incidence of arterial or venous thrombosis with COVID-19 made initial&#xD;
      recommendations regarding using higher doses of anticoagulation. The markers of thrombosis&#xD;
      like D-dimer, platelet count, fibrinogen are also increased in patients with COVID-19 along&#xD;
      with other inflammatory markers. The pathophysiology of coagulopathy of COVID-19 is still&#xD;
      under research. It is likely multi-factorial involving Inflammation, hypoxia, endothelial&#xD;
      dysfunction, direct viral cytopathic effect, platelets and complement activation, derangement&#xD;
      of the renin-angiotensin-aldosterone pathway.&#xD;
&#xD;
      From the inception of the pandemic, the physicians started using various antithrombotic with&#xD;
      higher than prophylactic doses to treat the prothrombotic state. In the absence of clear&#xD;
      guidance with conflicting evidence, there is considerable variation in the practices of&#xD;
      physicians managing COVID-19.&#xD;
&#xD;
      The investigators are planning for a nationwide multicentre cross-sectional survey on&#xD;
      understanding participating physicians practices on the choice of different antithrombotics&#xD;
      available in India as of August 2021.&#xD;
&#xD;
      The survey will have three sections: 1. Demographics 2. Antithrombotics in hospitalised&#xD;
      patients 3. Antithrombotics after discharge from the hospital&#xD;
&#xD;
      The investigators intend to involve 1000 physicians from different specialities with the help&#xD;
      of the steering committee.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 21, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Choice, dose, and indication of antithrombotics for management of COVID-19.</measure>
    <time_frame>two weeks</time_frame>
    <description>Through web-based cross-sectional survey will capture the practices of physicians on choice, dose, and indication of antithrombotics for management of COVID-19 during hospitalisation and post-discharge</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <condition>Thrombosis</condition>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Current clinical practices of participating physicians</intervention_name>
    <description>Current clinical practice of participating physicians on management of antithrombotics for COVID-19 during hospitalisation and post-discharge</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Physicians from different specialities like Internal Medicine, Pulmonary Medicine,&#xD;
        Anesthesiologists, Critical Care Medicine will be recruited through snowballing sampling. A&#xD;
        web-based cross-sectional survey will be circulated among the target population by the&#xD;
        investigators through e-mail and social media channels.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Physicians involved in the management of adult hospitalised patients with COVID-19 in&#xD;
        India&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pediatricians&#xD;
&#xD;
          -  Physicians involved in the out-patient management of COVID-19&#xD;
&#xD;
          -  Refused to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Prashant Nasa, MD EDICM</last_name>
    <role>Principal Investigator</role>
    <affiliation>NMC Specialty Hospital, Dubai, UAE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prashant Nasa, MD EDIC FNB</last_name>
    <phone>97142122255</phone>
    <email>dr.prashantnasa@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Reliance Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Mumbai, Mahrastra</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashant Nasa, MD EDICM</last_name>
      <phone>971501425022</phone>
      <email>dr.prashantnasa@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Bharat Jagiasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Chandra A, Chakraborty U, Ghosh S, Dasgupta S. Anticoagulation in COVID-19: current concepts and controversies. Postgrad Med J. 2021 Apr 13. pii: postgradmedj-2021-139923. doi: 10.1136/postgradmedj-2021-139923. [Epub ahead of print] Review.</citation>
    <PMID>33850011</PMID>
  </reference>
  <reference>
    <citation>Fontelo P, Bastola MM, Zheng Z, Baik SH. A review of thromboembolic events in hospitalized COVID-19 patients. Thromb J. 2021 Jun 29;19(1):47. doi: 10.1186/s12959-021-00298-3. Review.</citation>
    <PMID>34187490</PMID>
  </reference>
  <reference>
    <citation>Jagiasi B, Nasa P, Chanchalani G, Ahmed A, Ak AK, Sodhi K, Mangal K, Singh MK, Gupta N, Bidkar PU, Tyagi RS, Khanikar RG, Tripathy S, Khanzode S, Subba Reddy K, Saigal S, Sivakumar VA, Javeri Y, Tekwani SS. Variation in therapeutic strategies for the management of severe COVID-19 in India: A nationwide cross-sectional survey. Int J Clin Pract. 2021 Oct;75(10):e14574. doi: 10.1111/ijcp.14574. Epub 2021 Jul 18.</citation>
    <PMID>34171154</PMID>
  </reference>
  <reference>
    <citation>Liu Y, Cai J, Wang C, Jin J, Qu L. A systematic review and meta-analysis of incidence, prognosis, and laboratory indicators of venous thromboembolism in hospitalized patients with coronavirus disease 2019. J Vasc Surg Venous Lymphat Disord. 2021 Sep;9(5):1099-1111.e6. doi: 10.1016/j.jvsv.2021.01.012. Epub 2021 Jan 30.</citation>
    <PMID>33529719</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NMC Specialty Hospital</investigator_affiliation>
    <investigator_full_name>Prashant Nasa</investigator_full_name>
    <investigator_title>Head Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Anticoagulation in COVID-19</keyword>
  <keyword>Anticoagulants</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Coronavirus Disease 2019</keyword>
  <keyword>Management of COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

